Skip to main content
OpenTrials
Completed

NCT Number: NCT00618007

Effect of PF-00734200 in Subjects With Type 2 Diabetes

To determine the effect of PF-00734200 on HbA1c in type 2 diabetic subjects receiving metformin

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Pfizer Investigational Site, Coquitlam, British Columbia, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Men or women between 18-80 years of age with poorly controlled Type 2 diabetes

Exclusion criteria

Type 1 or secondary forms of diabetes Currently using insulin

Treatment and study plan

PF-00734200 30 mg QD

Drug

30 mg QD

PF-00734200 20 mg QD

Drug

20 mg QD

Placebo

Drug

Placebo

Primary outcomes

  1. HbA1c

    Time frame: 12 weeks

Secondary outcomes

  1. Fasting Glucose

    Time frame: 12 weeks

  2. Fasting Insulin

    Time frame: 12 weeks

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of 12-Week Administration Of PF-00734200 To Subjects With Type 2 Diabetes Mellitus And Insufficient Glycemic Control On Metformin Treatment

Important dates

Study start
2008
Primary completion
2008
Study completion
2008
First posted
Feb 18, 2008
Registry last updated
Jun 27, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.